Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: A pilot study

Complementary Therapies in Medicine

Volumn 13, Issue 4, 2005, Pages 273-278

  Cicero, Arrigo F G ^a   Brancaleoni, Marco ^b   Laghi, Luca ^a   Donati, Franco ^c   Mino, Marco ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Italian Association for the Study of Phytotherapy and Phytopharmacology   (Italy)

^c Difass Research and Development   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIF1STAT; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONASCUS PURPUREUS EXTRACT; NICOTINIC ACID; OCTACOSANOL; PLANT EXTRACT; PRAVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONASCUS; MONASCUS PURPUREUS; MUSCLE DISEASE; PILOT STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CAPSULES; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MONASCUS; NIACIN; PHYTOTHERAPY; PILOT PROJECTS; PLANT EXTRACTS; RISK;

EID: 29844458205     PISSN: 09652299     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctim.2005.07.008     Document Type: Article

References (27)

1. ATP III Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 19 2001 2486-2496
2. A.M. Gotto Jr. Treating hypercholesterolemia: Looking forward Clin Cardiol 26 Suppl. 1 2003 21-28
3. N. Buller D. Gillen R. Casciano J. Doyle K. Wilson A pharmacoeconomic evaluation of the myocardial ischaemia reduction with aggressive cholesterol lowering (MIRACL) study in the United Kingdom Pharmacoeconomics 21 Suppl. 1 2003 25-31
4. L.A. Prosser A.A. Stinnett P.A. Goldman L.W. Williams M.G. Hunink L. Goldman et al. Cost-effectiveness of cholesterol-lowering therapies according to patient characteristics Ann Intern Med 132 2000 769-774
5. T.A. Pearson T.L. Bazzarre S.R. Daniels J.M. Fair S.P. Fortmann B.A. Franklin et al. American heart association guide for improving cardiovascular health at the community level. A statement for public health practitioners, healthcare providers, and health policy makers from the American heart association expert panel on population and prevention science Circulation 107 2003 645-651
6. M.F. Caron C.M. White Evaluation of the antihyperlipidemic properties of dietary supplements Pharmacotherapy 21 4 2001 481-487
7. R. Platt Current concepts in optimum nutrition for cardiovascular disease Prev Cardiol 3 2 2000 83-87
8. D. Heber Herbs and atherosclerosis Curr Atheroscler Rep 3 1 2001 93-96
9. G.R. Norman D.L. Streiner Biostatistics The bare essential 2nd ed. 2000 B.C. Decker Inc. Hamilton Canada p. 139-44
10. M.D. Stuart Chinese materia medica - vegetable kingdom 1979 Southern Materials Center, Inc. Taipei, Republic of China
11. Ying SS. Tien Jung Kai Wu - Chinese technology in the seventeenth century (Sun ET, Sun SC, Trans.). London: Pennsylvania State University Press; 1966. p. 291-4.
12. D. Heber I. Yip J.M. Ashley D.A. Elashoff R.M. Elashoff V.L. Go Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement Am J Clin Nutr 69 2 1999 231-236
13. J.K. Keithley B. Swanson B.E. Sha J.M. Zeller H.A. Kessler K.Y. Smith A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia Nutrition 18 2 2002 201-204
14. R.Y. Man E.G. Lynn F. Cheung P.S. Tsang K. O Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2) Mol Cell Biochem 233 1-2 2002 153-158
15. D.J. Smith K.E. Olive Chinese red rice-induced myopathy South Med J 96 12 2003 1265-1267
16. G. Castano R. Mas L. Fernandez R. Gamez J. Illnait Effects of policosanol and lovastatin in patients with intermittent claudication: A double-blind comparative pilot study Angiology 54 1 2003 25-38
17. G. Castano R. Menendez R. Mas A. Amor J.L. Fernandez R.L. Gonzalez et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus Int J Clin Pharmacol Res 22 3-4 2002 89-99
18. G. Castano R. Mas L. Fernandez J. Illnait M. Mesa E. Alvarez M. Lezcay Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia Drugs Aging 20 2 2003 153-163
19. M.F. McCarty Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen Med Hypotheses 59 3 2002 268-279
20. S. Malik M.L. Kashyap Niacin, lipids, and heart disease Curr Cardiol Rep 5 6 2003 470-476
21. J. Simes C.D. Furberg E. Braunwald B.R. Davis I. Ford A. Tonkin et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The prospective pravastatin pooling project Eur Heart J 23 3 2002 207-215
22. S.H. Ganji V.S. Kamanna M.L. Kashyap Niacin and cholesterol: Role in cardiovascular disease J Nutr Biochem 14 6 2003 298-305
23. J. Kedward L. Dakin A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care Br J Gen Pract 53 494 2003 684-689
24. B. Weinhold Environmental cardiology: Getting to the heart of the matter Environ Health Perspect 112 15 2004 A880-A887
25. A.J. van Oostrom J. van Wijk M.C. Cabezas Lipaemia, inflammation and atherosclerosis: Novel opportunities in the understanding and treatment of atherosclerosis Drugs 64 Suppl. 2 2004 19-41
26. I.J. Kullo C.M. Ballantyne Conditional risk factors for atherosclerosis Mayo Clin Proc 80 2 2005 219-230
27. D.J. Rader Toward a higher standard: Raising HDL in clinical practice Medscape Cardiol 8 1 2004 1-9